New drug that could aid MS diagnoses approved for human trials by FDA

New drug that could aid MS diagnoses approved for human trials by FDA
Yanming Wang, co-inventor of Myeliviz and professor of radiology at the Case Western Reserve School of Medicine Credit: CWRU

A new drug that could make it easier for doctors to diagnose multiple sclerosis (MS) in its earlier stages has been approved for its first human trials by the U.S. Food and Drug Administration (FDA).

Created by Case Western Reserve researchers, the drug known as Myeliviz will be tested in clinical trials involving healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.

An autoimmune disease affecting 2.3 million people worldwide, according to the National Multiple Sclerosis Society (NMSS), MS can be a particularly difficult disease to diagnose. That's especially true in its early stages, due to unpredictable combinations of symptoms and their severity, and because of limitations in other available imaging methods.

Myeliviz (pronounced "MY-luh-viz"), targets and binds to —the sheathing surrounding nerves that is affected by MS—and allows for its imaging by a PET scanner, a common hospital tool.

The drug has the potential to provide a new source of evidence to help physicians determine the existence and extent of damage to the central nervous system (CNS) from MS.

The trials have been made possible by a $1.7 million grant from the National Institutes of Health.

"Myelin has never been directly imaged before. Our technique is the first to do so, and we are hopeful that this will provide earlier and more accurate diagnosis of MS," said Yanming Wang, co-inventor of Myeliviz and professor of radiology at the School of Medicine. He is also the co-principal investigator on the federal grant.

"The goal is to enable clinicians to more unambiguously diagnose MS and monitor disease progression and repair processes," said Robert Fox, vice chair for research in Cleveland Clinic's Neurological Institute and co-principal investigator on the grant.

How it works

Administered by an IV before a PET scan, Myeliviz targets and binds to myelin—acting as a marker in PET images. Normal myelin and damaged myelin have different patterns of Myeliviz uptake. Areas where myelin has been damaged appear as dark spots on the images, providing doctors with a potential new form of evidence to help determine MS diagnoses.

Given that MS can damage the CNS before its symptoms become apparent, the potential for earlier and more accurate diagnoses of the disease could help doctors use more effectively, such as during key early stages when the long-term severity of debilitating effects can be better influenced.

"Myeliviz could be the missing link in finding a cure for MS and other myelin diseases by serving as a specific and quantitative imaging marker for early diagnosis and sensitive, quantitative evaluation of novel therapies currently under development," said Chunying Wu, the drug's co-inventor and instructor of radiology at Case Western Reserve.

The combination of Myeliviz and PET imaging may be able to supplement, and perhaps in some cases replace, the use of magnetic resonance imaging (MRI) machines—which indirectly image myelin. The current standard-of-care imaging examination for MS, MRIs have long been used for diagnoses but are less effective for monitoring the disease.

"This drug may provide improved ongoing monitoring of brain health in general—and help doctors more accurately gauge the effectiveness of treatments in numerous neurological diseases such as epilepsy, stroke, neurodegeneration, tumor and trauma in the brain and spinal cord," said Mykol Larvie, director of functional neuroimaging at Cleveland Clinic, who leads efforts on the FDA application process.


Explore further

Breakthrough offers first direct measurement of spinal cord myelin in multiple sclerosis

Citation: New drug that could aid MS diagnoses approved for human trials by FDA (2020, January 27) retrieved 2 July 2020 from https://medicalxpress.com/news/2020-01-drug-aid-ms-human-trials.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments